SK Capital

Photo
17.05.2022 • News

H.I.G. Sells Valtris to SK Capital

Investment company H.I.G. Capital has agreed to sell Valtris Specialty Chemicals to an affiliate of funds managed by SK Capital Partners. Financial terms of the transaction were not disclosed. Based in Independence, Ohio, USA, the company manufactures specialty polymer additives and specialty chemicals at nine plants located around the world.

Photo
23.12.2021 • News

SK Capital Creates new CDMO from Seqens and Wavelength

Private equity group SK Capital Partners has completed the acquisition of a majority stake in French firm Seqens, at the same time merging portfolio company Wavelength Pharmaceuticals into Seqens to create a leading pharma CDMO with annual revenues of €1.1 billion. The size of SK Capital’s stake was not disclosed.

Photo
26.08.2021 • News

SK Capital Buys Deltech Businesses

Private equity company SK Capital Partners has purchased a majority stake in the monomers, polymers and European businesses of Deltech Holdings. Financial terms and the size of the stake were not disclosed, although Deltech’s founder and current president and CEO Bob Elefante is retaining a “significant” share and will remain actively involved in the company, including serving on the board of directors.

Photo
03.09.2020 • News

Huntsman Sells Venator Shares to SK Capital

Huntsman has agreed to sell about 42.5 million shares in Venator Materials – representing just below 40% of Venator’s outstanding shares – to private equity group SK Capital Partners for $100 million cash. The deal includes a 30-month option at $2.15/share for the remaining 9.5 million shares that Huntsman owns.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.